Harvard Bioscience, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $86.6M | $94.1M | $112.3M | $113.3M | $118.9M | $102.1M | $116.2M | $120.8M |
| Cost of Revenue | $36.6M | $39.4M | $46.2M | $52.5M | $51.3M | $44.1M | $51.9M | $57.6M |
| Gross Profit | $49.9M | $54.8M | $66.1M | $60.8M | $67.7M | $58.0M | $64.3M | $63.2M |
| Gross Margin | 57.7% | 58.2% | 58.9% | 53.7% | 56.9% | 56.8% | 55.4% | 52.3% |
| Operating Expenses | ||||||||
| Research & Development | $8.8M | $10.4M | $11.8M | $12.3M | $10.8M | $8.7M | $10.7M | $11.0M |
| SG&A Expense | $17.7M | $21.5M | $22.8M | $24.5M | $24.3M | $23.5M | $22.8M | $21.4M |
| Operating Income | $-48.6M | $-6.2M | $1.9M | $-6.9M | $2.1M | $221.0K | $377.0K | $984.0K |
| Operating Margin | -56.1% | -6.6% | 1.7% | -6.1% | 1.7% | 0.2% | 0.3% | 0.8% |
| Interest Expense | $3.6M | $3.2M | — | — | — | — | — | $5.4M |
| Pretax Income | $-57.4M | $-11.7M | $-2.6M | $-9.2M | $-140.0K | $-7.3M | $-5.5M | $-8.0M |
| Income Tax Expense | $-686.0K | $740.0K | $859.0K | $337.0K | $148.0K | $518.0K | $-815.0K | $-3.7M |
| Net Income | $-56.7M | $-12.4M | $-3.4M | $-9.5M | $-288.0K | $-7.8M | $-4.7M | $-2.9M |
| Net Margin | -65.5% | -13.2% | -3.0% | -8.4% | -0.2% | -7.6% | -4.0% | -2.4% |
| EPS (Basic) | $-1.28 | $-0.28 | $-0.08 | $-0.23 | $-0.01 | $-0.20 | $-0.12 | $-0.08 |
| EPS (Diluted) | $-1.28 | $-0.28 | $-0.08 | $-0.23 | $-0.01 | $-0.20 | $-0.12 | $-0.08 |
| Shares Outstanding (Basic) | 44.4M | 43.5M | 42.4M | 41.4M | 40.3M | 38.6M | 37.8M | 36.5M |
| Shares Outstanding (Diluted) | 44.4M | 43.5M | 42.4M | 41.4M | 40.3M | 38.6M | 37.8M | 36.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |